MX348677B - Peptidos ciclicos con actividad antineoplasica y antiangiogenica. - Google Patents

Peptidos ciclicos con actividad antineoplasica y antiangiogenica.

Info

Publication number
MX348677B
MX348677B MX2013010813A MX2013010813A MX348677B MX 348677 B MX348677 B MX 348677B MX 2013010813 A MX2013010813 A MX 2013010813A MX 2013010813 A MX2013010813 A MX 2013010813A MX 348677 B MX348677 B MX 348677B
Authority
MX
Mexico
Prior art keywords
cyclic peptides
systems
neoplasic
angiogenic activity
nanobiotechnology
Prior art date
Application number
MX2013010813A
Other languages
English (en)
Other versions
MX2013010813A (es
Inventor
Acosta Osvaldo Reyes
Santiago Glay Chinea
Diaz Eduardo Martinez
Pérez Maria Del Carmen Abrahantes
Blanco Sonia Gonzalez
Mola Ernesto Lopez
Perez Hilda Elisa Garay
Matilde Lopez Abad Cruz
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Publication of MX2013010813A publication Critical patent/MX2013010813A/es
Publication of MX348677B publication Critical patent/MX348677B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a péptidos cíclicos con propiedades antitumorales y antiangiogénicas, así como a sus sales farmacéuticamente aceptables y a las composiciones farmacéuticas que los contienen; estos péptidos cíclicos se emplean en la preparación de medicamentos para la terapéutica humana y/o veterinaria, y también pueden emplearse en el diagnóstico; estos compuestos pueden ser usados para detectar, monitorear y/o controlar una variedad de desórdenes relacionados con la proliferación celular, tales como las enfermedades oncológicas y la angiogénesis no deseada; además, pueden formar parte de sistemas de liberación controlada y en el campo de la nanobiotecnología, ya sea por su capacidad de autoensamblaje o como parte de otros sistemas.
MX2013010813A 2011-03-21 2012-03-21 Peptidos ciclicos con actividad antineoplasica y antiangiogenica. MX348677B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2011000067A CU23950B1 (es) 2011-03-21 2011-03-21 Péptidos cíclicos con actividad antineoplásica y antiangiogénica
PCT/CU2012/000002 WO2012126441A2 (es) 2011-03-21 2012-03-21 Péptidos cíclicos con actividad antineoplásica y antiangiogénica.

Publications (2)

Publication Number Publication Date
MX2013010813A MX2013010813A (es) 2013-10-07
MX348677B true MX348677B (es) 2017-06-23

Family

ID=46000593

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010813A MX348677B (es) 2011-03-21 2012-03-21 Peptidos ciclicos con actividad antineoplasica y antiangiogenica.

Country Status (16)

Country Link
US (1) US9375459B2 (es)
EP (1) EP2690107B1 (es)
JP (1) JP6032854B2 (es)
KR (1) KR101958964B1 (es)
CN (1) CN103534265B (es)
AR (1) AR088727A1 (es)
AU (1) AU2012231427B2 (es)
BR (1) BR112013024265B1 (es)
CA (1) CA2830325C (es)
CO (1) CO6801641A2 (es)
CU (1) CU23950B1 (es)
ES (1) ES2644554T3 (es)
MX (1) MX348677B (es)
RU (1) RU2603286C2 (es)
WO (1) WO2012126441A2 (es)
ZA (1) ZA201307037B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3024847A1 (en) * 2013-07-25 2016-06-01 Novartis AG Disulfide cyclic polypeptides for the treatment of heart failure
EP3024845A1 (en) * 2013-07-25 2016-06-01 Novartis AG Cyclic polypeptides for the treatment of heart failure
WO2015013165A1 (en) * 2013-07-25 2015-01-29 Novartis Ag Cyclic apelin derivatives for the treatment of heart failure
WO2015013169A2 (en) * 2013-07-25 2015-01-29 Novartis Ag Bioconjugates of synthetic apelin polypeptides
WO2015160770A1 (en) * 2014-04-15 2015-10-22 The Regents Of The University Of California Bi-terminal pegylated integrin-binding peptides and methods of use thereof
CN109503701B (zh) * 2018-07-20 2022-03-15 北京工业大学 一种环肽及其在制备抗肿瘤药物中的应用
GB201909509D0 (en) * 2019-07-02 2019-08-14 Immunocore Ltd Peptide-MHC complexes
CN111662363A (zh) * 2020-06-22 2020-09-15 上海大学 环肽类抗肿瘤活性化合物及其制备方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003264192A1 (en) 2002-08-30 2004-03-19 Biopharmacopae Design International Inc. Plant extracts for treatment of angiogenesis and metastasis
CU23475A1 (es) * 2004-07-08 2009-12-17 Ct Ingenieria Genetica Biotech Composición farmacéutica conteniendo fragmentos polipeptídicos de serralisinas
WO2007022557A1 (en) 2005-08-23 2007-03-01 Diatech Pty Ltd Mimotopes of epstein-barr virus (ebv) epitopes
CN101325963B (zh) * 2005-10-08 2016-01-27 博泰迪亚制药公司 用于眼部病症的补体抑制素和其类似物
ITTO20060852A1 (it) * 2006-11-30 2008-06-01 Univ Degli Studi Torino Peptidi metastasi-specifici e loro applicazioni diagnostiche e terapeutiche
JP5548616B2 (ja) * 2007-08-08 2014-07-16 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ｖｅｇｆｒ−１／ｎｒｐ−１標的化ペプチド
EP2303913A4 (en) * 2008-06-20 2013-07-24 Univ Texas CRECL TARGET PEPTIDES
US20100015058A1 (en) * 2008-06-25 2010-01-21 Stanford University Radiolabeled bbn-rgd heterodimers for cancer targeting

Also Published As

Publication number Publication date
CO6801641A2 (es) 2013-11-29
US20140112976A1 (en) 2014-04-24
US9375459B2 (en) 2016-06-28
AU2012231427B2 (en) 2016-08-04
CN103534265A (zh) 2014-01-22
ZA201307037B (en) 2014-06-25
WO2012126441A3 (es) 2012-11-22
WO2012126441A2 (es) 2012-09-27
BR112013024265A2 (pt) 2016-12-27
MX2013010813A (es) 2013-10-07
BR112013024265B1 (pt) 2020-12-08
CA2830325C (en) 2019-09-10
AU2012231427A1 (en) 2013-10-03
JP2014513066A (ja) 2014-05-29
RU2603286C2 (ru) 2016-11-27
JP6032854B2 (ja) 2016-11-30
CA2830325A1 (en) 2012-09-27
CU23950B1 (es) 2013-10-29
ES2644554T3 (es) 2017-11-29
AR088727A1 (es) 2014-07-02
KR101958964B1 (ko) 2019-07-02
KR20140042796A (ko) 2014-04-07
CN103534265B (zh) 2016-06-08
RU2013146690A (ru) 2015-04-27
EP2690107A2 (en) 2014-01-29
EP2690107B1 (en) 2017-08-02
CU20110067A7 (es) 2012-10-15

Similar Documents

Publication Publication Date Title
WO2012126441A3 (es) Péptidos cíclicos con actividad antineoplásica y antiangiogénica.
IL232308A (en) Compounds as modulators of atp-linked casting, pharmaceuticals containing them and their use in the preparation of drugs for the treatment of diseases and processes for their preparation
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
IL231226A (en) Compounds and preparations as kinase c-kit inhibitors, pharmaceutical preparations containing them and their use in the preparation of medicines for the treatment of diseases
IL230874A (en) History of dihydroquinoline-2-on-egg scallops, their preparation process, pharmaceutical preparations containing them and their use in the preparation of drugs
IL223795A (en) History of Tetrahydro-Pyrido-Pyrimidine
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
PH12015501096A1 (en) Composition for immediate and extended release
JO3122B1 (ar) مشتقات إسترا-5،3،1(10)، 16- تترايين-3- كربوكساميد، عمليات لتحضيرها، مستحضرات دوائية تشتمل عليها واستخدامها لتحضير أدوية
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
PH12012502082A1 (en) Combination of active loaded granules with additional actives
PH12013502325A1 (en) Drug delivery system
PH12012502083A1 (en) Manufacturing of active-free granules and tablets comprising the same
MX347105B (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona.
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
MX363699B (es) Producto de comicronizacion que comprende acetato de ulipristal.
UA117154C2 (uk) Антагоністи s1p3
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
WO2014007771A3 (en) Inhalation compositions comprising muscarinic receptor antagonist
IL225105A (en) Heterocyclic compounds, their process, their pharmaceutical preparations and their use in the preparation of drugs
MX2015007731A (es) Formulacion farmaceutica que comprende ciclesonida.
EP2682129A3 (en) Compositions Comprising Muscarinic Receptor Antagonist and Glucose Anhydrous
EP2682103A3 (en) Compositions Comprising Muscarinic Receptor Antagonist and Sorbitol

Legal Events

Date Code Title Description
FG Grant or registration